Chen C, et al. - Researchers sought to determine the prognostic impact of postresection intra-arterial chemotherapy (IAC) in patients with stage 2–3 gallbladder cancer (GBC) following curative resection. Two patient groups were formed: those who underwent 4 courses of intravenous chemotherapy (IVC) following 2 courses of IAC (ART group) post-resection, and those who received 6 courses of IVC (SYS group). Both the IAC and IVC regimens consisted of oxaliplatin (85 mg/m²) on day 1 and gemcitabine (800 mg/m²) on day 1 and day 8. Between the two groups, no different patient characteristics and chemotherapy complications were reported and no significant difference was found in 3-year disease-free survival. Overall, IAC afforded a safe and effective treatment option that could decrease postresection hepatic metastases and improve 3-year hepatic metastases-free survival and overall survival of stage 2–3 GBC.